FDA approves Breyanzi for relapsed, refractory marginal zone lymphoma
by Lori SolomonThe U.S. Food and Drug Administration has approved a new indication for Breyanzi (lisocabtagene maraleucel) for treating adults with marginal zone lymphoma (MZL) who have failed treatme
Updated on: December 27,2025
FDA approves Breyanzi for relapsed, refractory marginal zone lymphoma
by Lori SolomonThe U.S. Food and Drug Administration has approved a new indication for Breyanzi (lisocabtagene maraleucel) for treating adults with marginal zone lymphoma (MZL) who have failed treatme
Updated on:December 27,2025
